This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Not All HAs are Created Equal
DUROLANE’s key advantages matter for your knee OA patients
DUROLANE, a single-injection hyaluronic acid (HA) treatment, can significantly improve the quality of life for knee osteoarthritis (OA) patients as soon as 2 weeks after injection.20
DUROLANE has the highest reported molecular weight of any HA—1015kDa.‡43,46
Here are more of DUROLANE’s key advantages:
DUROLANE is a non-animal, stabilized HA that is cross-linked and entangled to create an HA with a long residence time.10
DUROLANE has:
- A half-life of 30 days (approximately 4 weeks) in the knee joint in a single-injection treatment regimen35
- The longest reported half-life of any HA32-35
DUROLANE is the only FDA-approved single-injection HA for the treatment of knee OA pain proven to be clinically equivalent to a five-injection therapy.13,24
In a Level 1 study:11
- DUROLANE was proven to be non-inferior to a steroid at 6 weeks.||
- Researchers found a significant reduction in WOMAC pain from baseline with DUROLANE vs a steroid at week 26 [p=0.034]¶
Find a sales representative or contact us with your questions about DUROLANE
‡Based on theoretical calculations
§Animal performance may not be predictive of performance in humans.
||Methylprednisolone acetate (MPA)
¶The primary outcome was the WOMAC pain responder rate, defined as at least 40% relative improvement and 5-point absolute improvement from baseline values at 12 weeks.